Aristotle University Of Thessaloniki (AUTH)
Η επίδραση της μπεβασιζουμάμπης σε πειραματικό μοντέλο ρευματοειδούς αρθρίτιδας
Abstract
dc:descriptionBackground/Aims: We studied the efficacy of VEGF inhibition through intra-articular (IA) injection of bevacizumab in antigen induced arthritis (AIA), an animal model of rheumatoid arthritis (RA). Methods: Female New Zealand White rabbits randomized in four groups. One group served as control (C). The three other groups were immunized. In immunized animals arthritis was induced by ovalbumin injection into the right knee joint space. After AIA induction they were anesthetized and randomized into three groups. One group served as the disease control (S) and was subjected to two IA injections of saline on days 1, 14. Second (B) and third (2xB) treatment group were also subjected to the same dosing regimen using IA injections of 1.25 mg and 2.5 mg of bevacizumab respectively. To evaluate the grade of arthritis/inflammation joint swelling, pannus formation and synovial fluid leucocyte counts were evaluated and compared with control groups. Histological evaluation of the infrapatellar fat pads was performed. Creatine kinase (CK), alkaline phosphatase activity, albumin and hemoglobin were determined. Serum ΙL-6 and CRP concentrations were measured using ELISA. Results: Group S differed from C statistically significantly in all parameters except hemoglobin. Treatment with bevacizumab in group B significantly reduced inflammatory reactions, ΙL-6 and CRP concentration and ameliorated histpathological findings compared to the disease control group (S). In addition, Cahexia was prevented as CK activity and serum albumin levels were normal. Alkaline phosphatase elevation was observed in group B, which was attributed to bone remodeling. Group 2xB showed a tendency to ameliorate inflammation and the two groups did not differ statistically significantly in most aspects. We observed that the 1.25 mg bevacizumab group tended to have milder inflammatory reaction compared to 2.5 mg group which led us to believe that excessive inhibition might be harmful. Moreover, anemia in 2xB group encountered as an adverse effect of bevacizumab. Conclusion: These findings confirm the predominant role of angiogenesis in the inflammatory process and suggest that bevacizumab could represent a promising novel therapeutic approach in the treatment of RA, especially through the IA route as an alternative to corticosteroids therapy. In addition, inhibition of angiogenesis should be maintained at a balance. Treatment should aim to inhibit VEGF excess, without affecting its normal levels, which are necessary to maintain vascular homeostasis. In conclusion, it seems that excessive VEGF blockade does not prevent the inflammatory process but exacerbates it.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tomos, Konstantinos
- Τόμος, Κωνσταντίνος
Subjects
dc:subject × 24- Μπεβασιζουμάμπη
- Αγγειογένεση
- Ρευματοειδής αρθρίτιδα (ΡΑ)
- Φλεγμονή
- Αγγειακός ενδοθηλιακός αυξητικός παράγοντας (VEGF)
- Αναστολή της αγγειογένεσης
- C - αντιδρώσα πρωτεΐνη (CRP)
- IL - 6 (Ιντερλευκίνη - 6)
- Αντιγονο - επαγόμενη αρθρίτιδα (AIA)
- Έγχυση ενδοαρθρική
- Bevacizumab
- Angiogenesis
- Rheumatoid arthritis (RA)
- Inflammation
- Vascular endothelial growth factor (VEGF)
- Inhibition of angiogenesis
- C-reacting protein (CRP)
- Interleukine - 6 (IL-6)
- Antigen induced arthritis (AIA)
- Intraarticular injection
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
dc:rights- Statement dc:rights
-
- BY_NC_SA
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44338